Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
Plain-language summary
This is a research study collecting clinical information and/or biological samples from patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
BCL regimen (DRUG): Induction therapy period (28 days\*6) Bendamustine; Specification: 100mg per vial; 90mg/m2 d1-2, ivgtt.; for age≤70 years; 70mg/m2 d1-2, ivgtt.; for age\>70 years; Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks, po.; for age≤70 years; 15mg biw for 2 weeks, po.; for age\>70 years; Lenalidomide Specification:10mg per tablet; 10mg qd d1-d21, po.; for age≤70 years; 10mg qd d1-d14, po.; for age\>70 years; | Cohort 1 (ASCT-eligible) (PROCEDURE): Autologous hematopoietic stem cell transplantation SEAM conditioning Simustine 250mg/m2 orally, d1; Etoposide 200mg/m2 intravenous infusion, d2-d5; Cytarabine 400mg/m2 intravenous infusion, d2-d5; Metformin 140mg/m2 intravenous infusion, d6; | Cohort 2 (ASCT--ineligible) (DRUG): Maintenance therapy period (2 years) Chidamide; Specification: 5mg per tablet; 15mg biw for 2 weeks per 3 weeks, po.;
BCL regimen, Cohort 1 (ASCT-eligible), Cohort 2 (ASCT--ineligible)
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details